Cancer Drugs Fund

Last updated

The Cancer Drugs Fund (CDF) was introduced in England in 2011. It was established in order to provide a means by which National Health Service (NHS) patients in England could get cancer drugs rejected by National Institute for Health and Care Excellence because they were not cost effective. Its establishment was confirmed by the UK government's coalition agreement in 2010, [1] and by the White Paper, Equity and excellence – Liberating the NHS. [2]

Contents

Starting in April 2011, the fund paid for nearly 100,000 people with cancer to access treatments. It was closed to new drugs from October 2015 to 29 July 2016 in line with the recommendation of the independent Cancer Taskforce report, which called for urgent reform to put the CDF on a more sustainable footing. [3]

Objectives

Following the reforms in 2016 the objectives were updated. The new arrangements put it on a more sustainable footing with 3 key objectives:

The previous objectives of the CDF, as set out by the UK government in 2011, [4] were that it should:

Operation

The patient's consultant must apply to the fund using an application form supplied by NHS England. Decision Summaries which are the formal decisions of the Chemotherapy Clinical Reference Group are published. [5]

Avastin is the most frequently requested treatment. Kadcyla is the most expensive drug funded. Both are manufactured by Hoffmann-La Roche, which has been described as the largest beneficiary of the fund. [6]

From July 2016 it became a "managed access" fund, paying for new drugs for a set period before they are definitively approved or rejected by the National Institute for Health and Care Excellence. It did not accept any new drugs between April and July 2016. From 2016 each drug has evaluation criteria and a timescale for effectiveness to be assessed. If it is considered to be cost effective it will be available to any patient. If not it will not be available at all in the English NHS. [7]

Pembrolizumab was added to the list in November 2022 after a "confidential" deal with manufacturer MSD. [8]

The current list of treatments funded by the CDF is available from the NHS England website: https://www.england.nhs.uk/cancer/cdf/cancer-drugs-fund-list/. It is regularly updated. In November 2022 it had reached version 1.238.

History

The funding system originally ran from April 2011 to March 2014, and was preceded by an Interim Cancer Drugs Fund from October 2010 to March 2011. Based on the size of their covered population, each strategic health authority in England was allocated fixed funds from a total £200 million per annum that was made available.

The fund overspent by £30m in the year ending 2014. In August 2014 it was announced that the CDF would receive £80 million in additional funding for the following 2 years. But in November 2014 it was announced that 42 drugs currently provided would be reassessed due to inadequate cost-effectiveness. [9] In Wales, the National Assembly debated the use of Cancer Treatment Fund and the Welsh Labour government was clear that it would not be replacing its existing evidence-based system with a cancer drugs fund. It relies on the All Wales Medicines Strategy Group which has appraised and recommended 19 new cancer medicines for use in NHS Wales covering 23 clinical indications. These are now routinely available to eligible patients in Wales but only 9 are available in England via the Cancer Drugs Fund. [10]

In May 2015 it was reported that only 59 of the 84 treatments previously funded would be supported in future, and that three new drugs would be included in the scheme. After a manufacturer's appeal Regorafenib was restored to the list. [11]

Criticism

Research indicates that society does not support the prioritisation of cancer drugs over other treatments. [12] The Financial Times attacked the fund in December 2014 as "a populist gesture that gives the impression of benefiting patients, but in fact rewards poor quality drugs while benefiting a handful of pharmaceutical companies at the expense of the taxpayer and the full range of NHS patients", complaining that it undermined the National Institute for Health and Care Excellence. [13]

James Le Fanu writing in The Daily Telegraph said "This mechanism for diverting taxpayers' money to enhance, to little or no purpose, the profits of Big Pharma might be more aptly named "the Drug Company Fund"." [14] In February 2015 York University researchers reported that the fund represented particularly poor value, diverting money from other patient services and that for every healthy year gained by this fund, five QALYs could be lost across the NHS. [15]

In December 2014 Andy Burnham announced that a Labour government would replace the fund with a Cancer Treatment Fund which would pay not only for innovative cancer drugs, but also for surgery and radiotherapy. It could mean increased access to advanced forms of radiotherapy such as intensity modulated radiotherapy and stereotactic ablative radiotherapy. [16]

In July 2015 the independent cancer taskforce established by NHS England proposed reform of the fund, which the taskforce said was "no longer sustainable or desirable… in its current form". [17]

Professor Karl Claxton, a health economist at the University of York, says that the fund should be scrapped because the money would be better used on 21,000 patients with heart, lung and gastro-intestinal diseases who are denied cost effective evidence based treatment, [18] arguing that the principal beneficiary of the fund is 'big pharma'. [19]

In September 2015 the National Audit Office reported that no data had been collected on the 74,000 patients whose treatment had been funded, at a cost of nearly £1 billion, so it was impossible to discover whether the treatment had been effective. [20]

The Public Accounts Committee published a report on the fund in February 2016 which concluded that there was no evidence the fund was benefiting patients, extending lives or a good use of taxpayers' money. [21]

Prof Richard Sullivan, of King's College London and Dr Ajay Aggarwal of the London School of Hygiene & Tropical Medicine published a study in the Annals of Oncology in April 2017. He concluded that the initiative as initially established was a "huge waste of money" and a "major policy error". The researchers studied the 47 treatments that were being funded by January 2015, of which only 18% met internationally recognised criteria for being deemed clinically beneficial. For those drugs where there was some evidence of benefit, the average was an extra 3.2 months of survival. The majority of patients were exposed to unpleasant side effects for no benefit. £1.27 billion was spent on the fund during the period studied. [22] No usable data was collected on what happened to patients whose treatment was funded - such as measuring how long they lived, their quality of life or side-effects. There was no consideration of the relative merits of surgery and radiotherapy. [23]

After its July 2016 reform, Eifiona Wood and Dyfrig Hughes from the Centre for Health Economics and Medicines Evaluation at Bangor University criticised decisions made by NICE on Drugs financed by the Cancer Drugs Fund for their lack of transparency, with decisions being made without disclosing ICERs (Incremental cost-effectiveness ratio) or total spending. They claim that this goes against NICEs own policy guidance and risks undermining its integrity. [24]

See also

Related Research Articles

An orphan drug is a pharmaceutical agent developed to treat medical conditions which, because they are so rare, would not be profitable to produce without government assistance. The conditions are referred to as orphan diseases.

<span class="mw-page-title-main">National Institute for Health and Care Excellence</span> Non-departmental public body of the Department of Health in the United Kingdom

The National Institute for Health and Care Excellence (NICE) is an executive non-departmental public body of the Department of Health and Social Care in England that publishes guidelines in four areas:

Professor Sir Bruce Edward Keogh, KBE, FMedSci, FRCS, FRCP is a Rhodesian-born British surgeon who specialises in cardiac surgery. He was medical director of the National Health Service in England from 2007 and national medical director of the NHS Commissioning Board from 2013 until his retirement early in 2018. He is chair of Birmingham Women's and Children's NHS Foundation Trust.

<span class="mw-page-title-main">NHS Wales</span> Publicly-funded healthcare system in Wales

NHS Wales is the publicly-funded healthcare system in Wales, and one of the four systems which make up the National Health Service in the United Kingdom.

The NHS treatments blacklist is an informal name for a list of medicines and procedures which will not be funded by public money except in exceptional cases. These include but are not limited to procedures which the National Institute for Health and Care Excellence (NICE) has ruled of limited effectiveness and particular brand name medicines. In 2017 there was a proposal for 3,200 over-the-counter (OTC) drugs to be restricted and 18 procedures to be added to the list. This generated some controversy amongst doctors with some arguing that OTC should be blacklisted instead, and others believing the move did not take into account individual patient needs.

Charges for prescriptions for medicines and some medical appliances are payable by adults in England under the age of 60. However, people may be exempt from charges in various exemption categories. Charges were abolished by NHS Wales in 2007, Health and Social Care in Northern Ireland in 2010 and by NHS Scotland in 2011. In 2010/11, in England, £450 million was raised through these charges, some 0.5% of the total NHS budget. In April 2021 the charge was raised to £9.35 for up to a three-month supply of each item. In 2022, for the first time since 2010, the charge was not increased.

Healthcare in the United Kingdom is a devolved matter, with England, Northern Ireland, Scotland and Wales each having their own systems of publicly funded healthcare, funded by and accountable to separate governments and parliaments, together with smaller private sector and voluntary provision. As a result of each country having different policies and priorities, a variety of differences have developed between these systems since devolution.

Imperial College Healthcare NHS Trust is an NHS trust based in London, England. It is one of the largest NHS trusts in England and together with Imperial College London forms an academic health science centre.

<span class="mw-page-title-main">Criticism of the National Health Service (England)</span>

Criticism of the National Health Service (England) includes issues such as access, waiting lists, healthcare coverage, and various scandals. The National Health Service (NHS) is the publicly funded health care system of England, created under the National Health Service Act 1946 by the post-war Labour government of Clement Attlee. It has come under much criticism, especially during the early 2000s, due to outbreaks of antibiotic resistant infections such as MRSA and Clostridium difficile infection, waiting lists, and medical scandals such as the Alder Hey organs scandal. However, the involvement of the NHS in scandals extends back many years, including over the provision of mental health care in the 1970s and 1980s, and overspends on hospital newbuilds, including Guy's Hospital Phase III in London in 1985, the cost of which shot up from £29 million to £152 million.

<span class="mw-page-title-main">National Health Service (England)</span> Publicly-funded healthcare system in England

The National Health Service (NHS) is the publicly funded healthcare system in England, and one of the four National Health Service systems in the United Kingdom. It is the second largest single-payer healthcare system in the world after the Brazilian Sistema Único de Saúde. Primarily funded by the government from general taxation, and overseen by the Department of Health and Social Care, the NHS provides healthcare to all legal English residents and residents from other regions of the UK, with most services free at the point of use for most people. The NHS also conducts research through the National Institute for Health and Care Research (NIHR).

Healthcare in England is mainly provided by the National Health Service (NHS), a public body that provides healthcare to all permanent residents in England, that is free at the point of use. The body is one of four forming the UK National Health Service as health is a devolved matter, there are differences with the provisions for healthcare elsewhere in the United Kingdom, and in England it is overseen by NHS England. Though the public system dominates healthcare provision in England, private health care and a wide variety of alternative and complementary treatments are available for those willing and able to pay.

<span class="mw-page-title-main">National Health Service</span> Publicly-funded healthcare systems in the United Kingdom

The National Health Service (NHS) is the umbrella term for the publicly funded healthcare systems of the United Kingdom (UK). Since 1948, they have been funded out of general taxation. There are three systems which are referred to using the "NHS" name. Health and Social Care in Northern Ireland was created separately and is often locally referred to as "the NHS". The four systems were established in 1948 as part of major social reforms following the Second World War. The founding principles were that services should be comprehensive, universal and free at the point of delivery—a health service based on clinical need, not ability to pay. Each service provides a comprehensive range of health services, free at the point of use for people ordinarily resident in the United Kingdom apart from dental treatment and optical care. In England, NHS patients have to pay prescription charges; some, such as those aged over 60 and certain state benefit recipients, are exempt.

University College London Hospitals NHS Foundation Trust (UCLH) is an NHS foundation trust based in London, United Kingdom. It comprises University College Hospital, University College Hospital at Westmoreland Street, the UCH Macmillan Cancer Centre, the Royal National ENT and Eastman Dental Hospitals, the Hospital for Tropical Diseases, the National Hospital for Neurology and Neurosurgery, the Royal London Hospital for Integrated Medicine and the Royal National Throat, Nose and Ear Hospital.

<span class="mw-page-title-main">Wythenshawe Hospital</span> Hospital in Manchester, England

Wythenshawe Hospital is a large NHS teaching hospital in Wythenshawe, South Manchester, England. It provides general medical services to the local and regional area as well as being a national centre for respiratory medicine and cardiothoracic surgery. It is one of the larger hospitals within Manchester University NHS Foundation Trust.

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types. By 2015 it had two US approvals for advanced cancers.

<span class="mw-page-title-main">Clatterbridge Cancer Centre NHS Foundation Trust</span>

The Clatterbridge Cancer Centre (CCC) is an NHS Foundation Trust, which specialises in the treatment of cancer. The centre is one of several specialist hospitals located within Merseyside; alongside Liverpool Heart and Chest Hospital, Alder Hey Children's Hospital, Liverpool Women's Hospital, and the Walton Centre.

<span class="mw-page-title-main">Simon Stevens</span> British health manager and civil servant

Simon Laurence Stevens, Baron Stevens of Birmingham, is a British public policy adviser, former CEO, and independent member of the UK House of Lords. He served as the eighth Chief Executive of the National Health Service in England from 2014 to 2021.

The Velindre University NHS Trust is an NHS Wales trust established in 1994 as a specialist provider of cancer services in Wales. It runs the Velindre Cancer Centre and the Welsh Blood Service. It also incorporates, on a hosted basis, two other NHS Wales organisations: the NHS Wales Informatics Service (NWIS) and the NHS Wales Shared Services Partnership (NWSSP).

The case of Ashya King concerns a boy named Ashya King, who suffered from a brain tumour. His parents, Brett and Naghemeh King, took their son out of Southampton General Hospital (England) in August 2014 over a disagreement with doctors regarding his treatment.

Professor Karl Claxton, is a health economist at the University of York.

References

  1. ↑ The Coalition: our programme for government , 2010
  2. ↑ Department of Health "Equity and excellence – Liberating the NHS", 2010
  3. ↑ England, NHS. "NHS England » Cancer Drugs Fund". www.england.nhs.uk. Retrieved 6 April 2017.
  4. ↑ Department of Health "The Cancer Drugs Fund: Guidance to support operation of the Cancer Drugs Fund in 2012-13", 2012
  5. ↑ "Cancer Drug Fund decision summaries". NHS England. Archived from the original on 7 September 2015. Retrieved 9 September 2015.
  6. ↑ "Cancer Drugs Face Axe In NHS Cost-Cutting Move". Sky News. 1 September 2015. Retrieved 13 September 2015.
  7. ↑ "Pharma firms to cover overspends on new cancer drugs fund". Health Service Journal. 29 February 2016. Retrieved 8 April 2016.
  8. ↑ "NHS reaches deal for life-saving breast-cancer drug". BBC. 8 November 2022. Retrieved 11 November 2022.
  9. ↑ "Cancer Drugs Fund to be restricted - says NHS". BBC News. 12 November 2014. Retrieved 13 November 2014.
  10. ↑ "Cancer Treatment Fund for Wales?". Socialist Health Association. 6 November 2014. Retrieved 13 November 2014.
  11. ↑ "Cancer fund reprieve for just one drug, Regorafenib". BBC. 22 May 2015. Retrieved 7 June 2015.
  12. ↑ Linley, W.G. & Hughes, D.A., 2012. Societal views on NICE, Cancer Drugs Fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Economics. "doi: 10.1002/hec.2872"
  13. ↑ "The Cancer Drugs Fund is a costly mistake". Financial Times. 15 December 2014. Retrieved 15 December 2014.
  14. ↑ Le Fanu, James (15 December 2014). "Health Secretary Jeremy Hunt and a 'creative' use of statistics". The Daily Telegraph. Archived from the original on 16 December 2014. Retrieved 15 December 2014.
  15. ↑ "NICE 'sets price too high for NHS medicines'". BBC News. 19 February 2015. Retrieved 22 February 2015.
  16. ↑ "Labour pledges cancer therapy fund". BBC News. 9 December 2014. Retrieved 15 December 2014.
  17. ↑ "Cancer commissioning overhaul could save 30,000 lives". Health Service Journal. 19 July 2015. Retrieved 19 July 2015.
  18. ↑ "Cancer Drugs Face Axe In NHS Cost-Cutting Move". Sky News. 1 September 2015. Retrieved 13 September 2015.
  19. ↑ Claxton, Karl (13 January 2015). "The UK's Cancer Drugs Fund does more harm than good". New Scientist. Retrieved 17 September 2015.
  20. ↑ "NHS failed to collect data on cancer treatment outcome". The Guardian. 17 September 2015. Retrieved 17 September 2015.
  21. ↑ "Cancer Drugs Fund 'should be managed better', say MPs". BBC News. 5 February 2016. Retrieved 9 February 2016.
  22. ↑ "Cancer Drugs Fund 'huge waste of money'". BBC News. 28 April 2017. Retrieved 28 April 2017.
  23. ↑ "The Cancer Drugs Fund, which Oxfordshire's Clive Stone fought to save, was 'not good value for money' according to new review". Oxford Mail. 28 April 2017. Retrieved 28 April 2017.
  24. ↑ Eifiona, Wood; Hughes, Dyfrig (2020). "The new and non-transparent Cancer Drugs Fund" (PDF). PharmacoEconomics. 38 (1): 1–4. doi:10.1007/s40273-019-00871-9. PMID   31828737. S2CID   208426661.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.